What 1,500 Kidney Transplants Means for Your Surgeon's Experience — and Your Outcome
When choosing a hospital for a kidney transplant, the question most families ask is: what is the success rate? It is a reasonable question. But it is also the wrong first question because 'success rate' is a single number that averages across a wide range of patients, procedures, complications, and outcomes, and can be defined in multiple ways by different centres. The better question is: what does the team's accumulated experience mean for my specific situation?
At KIMS Secunderabad, more than 1,500 kidney transplants have been performed. This post explains what that number means in practical, clinical terms not as a credential for its own sake, but as a specific answer to the question: how does experience at this volume change what happens to a transplant patient when things are straightforward, when they are complicated, and when they go wrong?
Why transplant volume matters — the clinical case
Recognising rejection before it becomes irreversible
Acute rejection the immune system attacking the transplanted kidney is the most common serious complication in the first year after transplant. It occurs in approximately 10 to 15% of transplant recipients despite immunosuppression. At KIMS, the nephrology team has managed hundreds of rejection episodes acute cellular rejection, antibody-mediated rejection, and mixed patterns with elements of both.
The difference between a team with this volume of experience and a team at a lower-volume centre is not theoretical. The experienced team recognises subtle early signs of rejection a gradual rise in creatinine of 10 to 15% over 3 days that might be attributed to dehydration elsewhere, an unexpected change in urine output that prompts an earlier transplant biopsy and initiates treatment before the rejection becomes established and potentially irreversible.
The management of rejection also involves complex immunological decision-making: when to add pulse steroids, when to proceed to anti-rejection antibody therapy (ATG or rituximab), when to add plasmapheresis for antibody-mediated rejection, and when a biopsy is needed to distinguish acute rejection from calcineurin inhibitor toxicity (which looks similar biochemically but requires a completely different management response). These decisions require not just knowledge of the protocols but the clinical pattern-recognition that comes from seeing many cases. The 1,500+ KIMS transplant programme has provided this experience.
ABO-incompatible protocol refinement
ABO-incompatible transplant — transplanting across a blood group barrier using rituximab desensitisation and plasmapheresis is not a procedure that can be done well the first few times. The optimal rituximab timing, the target isoagglutinin titre threshold, the number and frequency of plasmapheresis sessions needed for a given baseline titre, the post-transplant monitoring intensity, and the response to titre rebound in the immediate post-transplant period all of these management decisions are refined through accumulated experience with a defined protocol. At KIMS, the ABO-incompatible programme has been performed repeatedly and its protocol has been validated by its outcomes. This is the difference between a centre that has performed 3 ABO-incompatible transplants and a centre that has performed 30 the protocol at KIMS is not theoretical but tested.
Delayed graft function (DGF)
Delayed graft function (DGF) occurs when the transplanted kidney does not work immediately after surgery the patient remains dialysis-dependent for days to weeks while the kidney recovers from preservation injury or ischaemia. DGF occurs in approximately 25 to 40% of deceased donor transplants and a smaller proportion of living donor transplants.
Managing a patient through DGF requires: CRRT or intermittent haemodialysis to keep the patient in electrolyte balance while the kidney is not working, careful monitoring to distinguish DGF from acute rejection (which can appear identical biochemically both cause absent or minimal urine output but require opposite management), transplant biopsy at the right time to clarify the diagnosis, and immunosuppression adjustment to balance the risk of under-immunosuppression (leading to rejection) against over-immunosuppression. At KIMS, DGF has been managed many times the team knows the clinical trajectory and calibration required.
Post-transplant infection management
The immunosuppression required to prevent rejection simultaneously reduces the immune system's ability to fight infections particularly opportunistic infections that are rare in immunocompetent people but common in transplant recipients. CMV disease (cytomegalovirus), BK virus nephropathy, Pneumocystis jirovecii pneumonia, and invasive fungal infections are all documented post-transplant complications that require specific diagnosis and treatment.
Managing these infections requires recognising them which is harder than it sounds. BK virus nephropathy, for example, produces a rising creatinine that is clinically indistinguishable from acute rejection. Without BK viraemia screening and a low threshold for transplant biopsy, BK nephropathy is easily treated as rejection with increased immunosuppression that makes the BK infection dramatically worse. The KIMS team screens for BK viraemia at defined intervals, maintains a low biopsy threshold for any unexplained creatinine rise, and has managed multiple cases of BK nephropathy and other opportunistic infections. The institutional experience that this provides is directly protective for the next patient.
What experience means for the ABO-incompatible patient specifically
The question of transplant volume matters most for ABO-incompatible candidates because ABO-incompatible transplant is a more complex procedure at every stage than compatible transplant. The pre-conditioning protocol, the peri-operative monitoring, and the post-transplant surveillance are all more intensive. The consequences of errors at any stage are greater. This is a procedure that requires a team that has done it enough times to have internalised every step, that has encountered the edge cases (baseline titre that does not fall despite full plasmapheresis protocol, post-transplant titre rebound, combined acute cellular and antibody-mediated rejection), and that has the institutional decision-making framework to manage them when they occur.
The KIMS ABO-incompatible programme provides this institutional depth, ensuring that patients crossing the blood group barrier are managed with the highest level of clinical safety and expertise.
The continuity of care — same team from first consultation to lifelong monitoring
Beyond the volume of procedures, what distinguishes the KIMS transplant programme is continuity. The DM Nephrology-qualified nephrologist who evaluates a patient during the pre-transplant workup reviewing the donor-recipient crossmatch, assessing cardiovascular fitness, discussing ABO-incompatible desensitisation is the same physician managing the patient's immunosuppression post-transplant, conducting the annual surveillance biopsy, and advising on the management of any long-term complication that arises in year 5 or year 10. There is no transfer of care between teams at different stages of the transplant journey. The patient's medical history does not need to be reconstructed each time because the team that knows it has not changed.
When evaluating transplant centres, ask specifically: who manages post-transplant care? Is it the same team that performs the transplant, or are patients transferred to a different physician or institution for ongoing monitoring?
The transplant is a 2 to 4 hour operation. The post-transplant management immunosuppression monitoring, rejection management, infection surveillance, long-term kidney function optimisation lasts for the lifespan of the graft. The team you choose for the surgery is the team you need for the next 15 to 20 years.
Frequently Asked Questions — Kidney Transplant at KIMS
More than 1,500 kidney transplants — including living related, living unrelated (with SAC approval), deceased donor, ABO-incompatible (blood group mismatch), and swap (paired kidney exchange) transplants. KIMS Secunderabad is NOTTO registered for deceased donor listing and TSTA empanelled for swap transplants. The programme has been active for over two decades and continues to perform transplants around the clock, with 24/7 availability for deceased donor calls.
Graft survival at KIMS is consistent with international standards for high-volume transplant centres. As a general benchmark: living donor 1-year graft survival at experienced centres exceeds 95%; deceased donor 1-year graft survival exceeds 90%. Five-year graft survival for living donor transplants exceeds 80 to 85% at high-volume programmes. The KIMS programme has been independently recognised with the Times Healthcare Achievers — Best Hospital of the Year in Nephrology.
Three specific differences matter clinically: First, ABO-incompatible transplant — KIMS performs transplants across blood group barriers with specialized protocols. Second, swap (paired kidney exchange) transplant coordinated through TSTA. Third, continuity — the same DM Nephrology-qualified nephrologist manages the patient from pre-transplant evaluation through to lifelong post-transplant care, ensuring your medical history stays with the team that knows it best.
Yes — KIMS manages re-transplants for patients whose prior grafts have failed. While technically more challenging due to adhesions and elevated panel reactive antibody (PRA) levels, the KIMS team manages these cases with specific desensitisation approaches and coordinates with NOTTO for deceased donor re-listing. Prior graft failure is not a reason to conclude that further transplantation is impossible.
Yes — kidney transplant (living and deceased donor) is covered under Aarogyasri (PMJAY) at KIMS Secunderabad up to the defined package rate. KIMS is also empanelled under CGHS and EHS. We recommend bringing your Aarogyasri card and Aadhaar at the first visit, as pre-authorisation takes several working days and should begin early in the evaluation process.
The complete evaluation — covering medical fitness, HLA typing, crossmatch, and ethics review — typically takes 6 to 8 weeks. ABO-incompatible cases may add 4 to 6 weeks for the desensitisation protocol. The process moves faster when investigations are initiated promptly, and our transplant coordinator helps manage the scheduling of each step.
As soon as possible — ideally even before dialysis starts (pre-emptive transplant). Evidence consistently shows that transplant outcomes are better the shorter the pre-transplant dialysis period. At KIMS, the transplant evaluation conversation begins at the first dialysis consultation for every eligible patient, as the benefit in survival and quality of life applies at every point in the journey.